Document:

Exhibit 10.3

 

		Letter
                                         of Clarification
	 

 

July
15th, 2020

 

Mr.
Matt Nicosia

CEO,
VIVAKOR Inc.

 

RE:
Invoice/Operating Charter SOLV-VIV-001

 

With respect
to the initial Agreement between Vivakor and solvAQUA; solvAQUA wishes to append such agreement with the following clarifications.

 

1.
solvAQUA acknowledges Vivakor's key technology is the Remediation Processing Center (RPC) that separates hydrocarbons from dry
soil. The RPC is currently being used in remediation projects in Vernal Utah to extract oil from the dry oil sands and in Kuwait
to clean up large scale oil spills.  Understanding that Vivakor wants to combine the solvAQUA technology to allow it to deal
with remediation projects that have a combination of wet and dry opportunities both in existing locations and new opportunities
globally which may include but not be limited to immediate projects on Native American lands; solvAQUA hereby grants to Vivakor
an exclusive license to incorporate its technology platform into scenarios such as described above for a term of ONE YEAR. Upon
successful installation and deployment of Vivakor initial TWO WMS UNITS such term shall be extended to FIVE YEARS. 

 

In
addition, understanding through its field operation activities and relationships, Vivakor may from time to time have the opportunity
to deploy the technology for cleaning other waste streams such as, but not limited to: produced water, tank bottom sludge and mining
water clean up; SUBJECT TO initial conditions being met as described above; solvAQUA shall grant to Vivakor a non-exclusive license
to deploy the technology on a case by case basis for the same term as above.

 

2.
Due to AHS (Alberta Health Services) and Government of Canada COVID 19 Guidelines and Restrictions; solvAQUA hereby exercises its
rights under the terms of the invoice SOLV-VIV-001 to extend delivery of units to October 31st, 2020. Accordingly, solvAQUA again
has the right to further adjust the timeline as per the above referenced Guidelines. Initial payment is due upon completion of
the machinery. 

 

We
trust the above to be satisfactory and an accurate reflection of our discussions regarding same.

 

 

 

Chris
Tesarski

CEO,
solvAQUA Inc.Exhibit 10.4

 

INTELLECTUAL PROPERTY LICENSE AGREEMENT

 

This Intellectual Property
Agreement (the “Agreement”) is hereby entered into effective as of September 30, 2020 (the “Effective Date”),
by and between, BGreen, LLC, a Utah limited liability company (“BGRE”, the “Licensor”) and
Vivakor, Inc., a Nevada corporation (“Vivakor”, the “Licensee”). The Licensee and the Licensor
may each be referred to herein as a “Party” and together as the “Parties.”

 

 1. RECITALS

 

A.       WHEREAS,
Licensor is the owner of certain intellectual property related to a cavitation technology suitable to improve the viscosity of
heavy crude, as described in Exhibit A, hereto (the “Cavitation Technology”), which Licensee is
interested in licensing from Licensor for the purpose of developing commercially-viable applications using the intellectual property;

 

B.       WHEREAS,
the Parties are parties to a certain Letter of Intent dated February 20, 2020, under which the Parties agreed to joint development
and commercialization of “Cavitation Technology” in Utah and other locations where VIVK operates its hydrocarbon extraction
technology. (the “Letter of Intent”).

 

C.       The
Parties desire that Licensor grant an exclusive license to Licensee for applications and implementations involving the Cavitation
Technology as set forth herein.

 

NOW, THEREFORE, in
consideration of the promises and agreements set forth below and the other considerations cited herein, the Parties agree as follows.

 

 2. DEFINITIONS

 

As used in this Agreement,
the following terms shall be defined as set forth below:

 

		2.1.	“Confidential Information” shall mean any and all information disclosed by a Party
(the “Disclosing Party”) to the other party (the “Recipient”) hereunder that is clearly marked or identified
as “confidential,” such as proprietary information relating to the Disclosing Party’s technology (including the
Intellectual Property and any associated knowhow), products, processes, business information, or intellectual property rights.
“Confidential Information” further includes the terms and conditions of this Agreement not otherwise made public by
agreement of the parties as well as information arising or disclosed pursuant to this Agreement. Notwithstanding the foregoing,
information will not be considered “Confidential Information” to the extent the Recipient can demonstrate by written
record or other suitable physical evidence that:

		a)	such specific information was lawfully in the Recipient’s possession or control prior to
the time such information was disclosed to the Recipient by the Disclosing Party;

 

 

 

 

    	 	1	 

     

    

 

		b)	such specific information was independently developed by one or more employees or other agents
of the Recipient without reference to such Confidential Information;

		c)	such specific information was lawfully obtained by the Recipient from a third party under no obligation
of confidentiality to the Disclosing Party; or

		d)	such specific information was, at the time it was disclosed or obtained by the Recipient, or thereafter
became, publicly known otherwise than through a breach of the Recipient’s obligations hereunder.

 

		2.2.	“Improvements” shall mean inventions or other improvements which relate to or are based
on the Inventions and which are within the scope of the then existing Intellectual Property. An Improvement shall be within the
scope of a patent in the Intellectual Property if covered by a claim, either literally or under the doctrine of equivalents.

 

		2.3.	“Intellectual Property” shall mean:

		a)	all issued patents, continuations, continuations-in-part, divisionals, and other patents or applications
derived from the Cavitation Technology;

		b)	all related knowhow and trade secrets relating to the Cavitation Technology; and

		c)	all other trade secrets and intellectual property information related to the Cavitation Technology.

 

		2.4.	“Licensed Products” shall mean the cavitation device built from the licensed Intellectual
Property in 2.3,

 

		2.5.	"New Invention(s)" shall mean an invention conceived or reduced to practice by Licensee
or jointly by Licensee and Licensor which relates to or is based on the subject matter of the Intellectual Property or on work
developed under the direction of Licensor, but which is outside the scope of the then-existing Intellectual Property.

 

		2.6.	“Net Profit” shall mean gross revenue minus cost of goods and marketing expense for
the manufacture and sale of the cavitation device by the Licensee.

 

		2.7.	“Party” (and collectively, “Parties”) shall mean either or collectively
the Licensor and/or Licensee, and all associated affiliates. Affiliates shall include a) any officer, director, and/or legal entity
directly or indirectly controlled by, or controlling, a Party, b) an entity of which fifty percent or more of the voting stock
is controlled or owned directly by a Party; c) an entity which owns fifty percent or more of the voting stock of a Party; and e)
an entity the majority ownership of which is directly or indirectly common to the majority ownership of a Party.

 

		2.8.	“Sublicensee” shall mean third parties to whom the Licensee sublicenses the Intellectual
Property pursuant to the terms of this Agreement to develop, manufacture, have manufactured, use, and sell the Licensed Products.

 

		2.9.	“Sublicensee Income” shall mean compensation or consideration of any kind received
by Licensee from a Sublicensee, including without limitation cash, marketable securities, stock or shares, and any tangible or
intangible assets.

 

 3. GRANT OF LICENSE

 

		3.1.	Grant. Subject to the terms and conditions of this Agreement, Licensor grants and the Licensee
hereby accept a worldwide, exclusive, non-transferable license in the Intellectual Property to develop, manufacture, have manufactured,
use, market, import, have imported, offer for sale, and sell the Licensed Products. This license grant shall be for the lifetime
of the Intellectual Property.

 

 

 

 

    	 	2	 

     

    

 

		3.2.	Sublicense. The Licensee shall have the right to sublicense the Intellectual Property to
third parties (hereinafter “Sublicensee”), subject to the prior written consent of Licensor, whose consent shall not
be unreasonably withheld. The sublicense terms shall be commercially reasonable when compared to similar transactions conducted
at arms-length, and no sublicense shall contain the right to grant further sublicenses without the prior written consent of Licensor.

 

		3.3.	Retention of Rights. Licensor shall retain the non-transferable right to make, use and practice
the Intellectual Property for his own noncommercial purposes. The license granted hereunder shall not be construed to confer any
rights upon Licensee by implication, estoppel or otherwise as to any technology or intellectual property other than the Intellectual
Property.

 

		3.4.	Third Party Licenses. The parties recognize that Licensee may encounter patents held by
third parties, and that licenses between Licensor or Licensee and such third parties may be necessary in order to enable the Licensee
to develop, make or market certain Licensed Products. In that event, the Licensee have the right to enter into licensing agreements
with such third parties, provided Licensor is consulted before hand, is reasonably satisfied that the third party does in fact
hold a patent that limits Licensee’s rights in respect of the making, using and/or marketing the Licensed Products, and Licensor
gives its written approval to such license, which approval shall not be unreasonably withheld. Any money received by Licensee in
exchange for such cross-licensing shall be treated as consideration from Sublicensee for sublicensing.

 

 4. PAYMENTS FOR THE LICENSE

 

	 	4.1	Payments.
All payments due to the Licensor for the License to the Intellectual Property are as follows:

 

		4.1.1.	Licensor shall participate in 50% of Net Profit.

		4.1.2.	Licensee shall, upon successfully
                                         improving and manufacturing a cavitation device with a 30 barrels per hour processing
                                         rate, Licensor shall make a payment to Licensor, which will be 1,000,000 shares of the
                                         Licensee’s common stock, issued to Licensor (the “Shares”). The Shares
                                         of the Licensee’s stock for payment will be subject to adjustment from time to
                                         time as follows:

		(i)	If the Licensee at any time
                                         or from time to time after the date of this Agreement fixes a record date for the effectuation
                                         of a split or subdivision of the outstanding shares of its common stock or the determination
                                         of holders of common stock entitled to receive a dividend or other distribution payable
                                         in additional shares of common stock or other securities or rights convertible into,
                                         or entitling the holder thereof to receive directly or indirectly, additional shares
                                         of common stock (hereinafter referred to as “Common Stock Equivalents”) without
                                         payment of any consideration by such holder for the additional shares of common stock
                                         or the Common Stock Equivalents (including the additional shares of Common Stock issuable
                                         upon conversion or exercise thereof), then, as of such record date (or the date of such
                                         dividend, distribution, split or subdivision if no record date is fixed), will be appropriately
                                         increased in proportion to such increase of the aggregate of shares of Common Stock outstanding
                                         and those issuable with respect to such Common Stock Equivalents.

		(ii)	If the number of shares of
                                         Licensee’s common stock outstanding at any time after the date of this Agreement
                                         is decreased by a combination of the outstanding shares of common stock, then, following
                                         the record date of such combination, Shares will be appropriately decreased in proportion
                                         to such decrease in outstanding shares. 

		4.1.3.	The Shares will be issued within
                                         30 days upon the threshold being met. The shares will contain standard restrictive legends.

		4.1.4.	Licensee shall pay $5,000USD
                                         to purchase the first simple cavitation device that is in Licensee’s possession.
                                         In addition, this payment includes a 50% discount on engineering consultation from Licensor
                                         of up to 60 hours for the manufacturing, setup and operation of the first 3D cavitation
                                         plate.

		4.1.5.	Licensee shall pay Licensor for additional engineering support fees of up to $3,000USD per month
for approximately 15-20 hours of offsite consultation, design or engineering. The first 3 months will be at a 50% discount. Travel
or onsite consulting fees will be negotiated mutually in good faith as needed. Licensee shall notify, in writing, Licensor when
engineering support is needed. If engineering support is not needed no such fee shall be paid.

 

 

 

 

    	 	3	 

     

    

 

		4.1.6.	Licensor hereby grants Licensee a first right of refusal to purchase all devices and all Intellectual
Property associated with the Cavitation Technology.

		4.1.7.	Licensee shall store one storage container containing machinery belonging to the Licensor for the
Licensor for up to 12 months as both parties work together to improve, manufacture and commercialize various solutions.

 

 5. REPORTS AND RECORDS

 

	 	5.1.	Record Retention. Licensee shall make and retain and shall cause its Sublicensee to make and retain, for a period
of three (3) years following the period of each report required by the Article true and accurate records of the account containing
all the data reasonably required for the full computation and verification of gross sales, gross revenues, and other information
for use by Vivakor to calculate any amounts due and owing to the Parties. Such records shall be in accordance with generally accepted
accounting principles consistently applied and shall be kept at Licensee’s principal place of business. The Licensee and
any of their Sublicensee shall permit the inspection of such records by an independent certified public accountant chosen by Licensor
and reasonably acceptable to Licensee during regular business hours upon five (5) business days’ written notice to Licensee,
to the extent necessary to verify compliance with this Agreement. Such inspection shall not be made more than once each calendar
year unless an error is discovered, or for other good cause. All costs of such inspection and copying shall be paid by Licensor,
provided that if any such inspection shall reveal that an error has been made in an amount equal to 5% or more of any such payment
due, such costs shall be paid by Licensee.

 

6. DUE DILIGENCE IN COMMERCIALIZATION

 

	 	6.1	Reasonable Efforts. Licensee agree that they shall use its reasonable efforts and diligently endeavor to achieve
the development, regulatory approval, and commercialization of the Licensed Products. Licensee may conduct such efforts itself
or through a Sublicensee.

 

	 	6.2	Termination. If, after a period of three (3) years from the Effective Date, the Licensee have not commercialized
a Licensed Product, Licensor shall have the right, at its option to: (a) terminate the Agreement; or, (b) convert any or all of
the rights granted to Licensee from exclusive to non-exclusive.

 

	 	6.3	Status Reports. Licensee shall provide periodic Status Reports to Licensor, at least quarterly, indicating progress
and problems to date in commercialization of the Licensed Products. Such Status Reports shall also include a forecast and schedule
of major events required to market the Licensed Products. Licensor shall treat all such information as confidential.

 

 7. PATENT PROSECUTION

 

	 	7.1.	Patent Prosecution Expenses. Beginning from the Effective Date and during the term of this Agreement and subject
to Section 7.7, Licensor shall diligently prosecute and maintain, at the Licensee’s expense, any United States and foreign
patents comprising the Intellectual Property, using patent counsel of the Licensee’s choice that is reasonably acceptable
to Licensee.

 

	 	7.2.	Patent Prosecution Cooperation. The Parties agree to fully cooperate with one another and to keep each other fully
informed regarding the preparation, filing, and prosecution of all patent applications which Licensor may file and prosecute pursuant
to this Agreement. Licensee will also execute and deliver all documents which Licensor may deem necessary or desirable for the
Intellectual Property. Licensor will also promptly provide copies of all documents received from any patent office, so as to keep
Licensee informed of the continuing prosecution. The Parties agree that representatives of each Party shall meet periodically to
review and keep one another fully informed as to the status of all Intellectual Property and all patent-related matters. Such representatives
may meet in person or telephonically, as mutually agreed upon by the Parties.

 

 

 

    	 	4	 

     

    

 

	 	7.3.	Protection of Licensed Products. Licensor will use reasonable efforts to amend any patent application to include
claims reasonably requested by the Licensee to protect the Licensed Products.

 

	 	7.4.	Foreign Protection of Licensed Products. The Licensee will have the right to request that Licensor obtain or maintain
patent protection on the Intellectual Property in foreign countries if possible or available. Licensee shall notify Licensor in
writing of the countries in which it desires to obtain or maintain foreign patents not less than sixty (60) days prior to the deadline
for any payment, filing, or action to be taken in connection therewith, and Licensee shall be responsible for all associated costs.
Upon receipt of such request, Licensor will undertake the actions described in Section 7 with respect to each foreign country requested
by Licensee and shall timely file any applicable patent applications. Licensee will be responsible for all costs associated with
such a request.

 

	 	7.5	Patent Marking. The Licensee and their Sublicensee shall mark all Licensed Products sold by it with appropriate patent
markings indicating that the Licensed Products are protected by one or more of patents in the Intellectual Property, if applicable.
All Licensed Products shipped to or sold in other countries shall be marked in such a manner as to conform to the patent laws and
practices of the country of manufacture or sale.

 

	 	7.6	Decision Not To file. If Licensor decides to take steps which would result in either not filing a patent application
or the abandonment of a patent or patent application, it shall promptly give notice to Licensee of such decision, which notice
shall in no event be less than thirty (30) days prior to the next deadline for payment, filing, or any other related action. Further,
Licensor shall provide Licensee an opportunity to assume responsibility for such patent application or patent.

 

	 	7.7	Decision Not To pay. At any time, upon providing sixty (60) days written notice, Licensee may discontinue making
payments with regard to any patent application(s) and/or patent(s) within the Intellectual Property, and in such case, Licensee
shall have no further rights under this Agreement and this license shall terminate with respect to those patent applications and/or
patents.

 

	 	7.8	Patent Extension. With respect to any issued patent in the Intellectual Property, Licensor will designate Licensee
as its agent for obtaining an extension of such patent or governmental equivalent which extends the exclusivity of any of the patent
subject matter where available in any country in the world, or if not feasible, at Licensee’s option, permit Licensee to
file in Licensor’s name or diligently obtain such extension for the Licensee, or their Sublicensee at Licensee’s expense.
Licensor agrees to provide reasonable assistance, at no out-of-pocket expense, to facilitate Licensee’s efforts to obtain
any extension. If for any reason the Licensee fail to exercise diligent efforts to obtain any extension or determine that it will
not seek such extension, the Licensee shall provide reasonable assistance, at no out-of-pocket expense, to facilitate Licensor’s
efforts to obtain any such extension.

 

 8. INFRINGEMENT

 

	 	8.1.	Notice of Infringement. The Parties shall promptly give written notice to each other of any apparent infringement
discovered with respect to any patent issuing from the Intellectual Property. Such notice shall set forth the known facts of the
apparent infringement in reasonable detail. Upon written notice to Licensor, the Licensee shall have the first right, but not the
obligation, to bring any legal action with respect to such apparent infringement at its own expense and for its own benefit. In
such event, Licensor agrees to cooperate with the Licensee and to join in such action as a party plaintiff if requested to do so
by the Licensee and, at the Licensee’s request, to give the Licensee all needed information, assistance, and authority to
file and prosecute such suit. The Licensee shall reimburse Licensor for all verified out-of-pocket expenses incurred by Licensor
in providing such assistance, including attorneys’ fees, expenses, and expert witness fees incurred by Licensor. To ensure
that no rights of Licensor are compromised in any such action, the Licensee shall not settle any such claim or action, or enter
into any settlement agreement that admits that any third party product does not infringe the Intellectual Property or that any
patent in the Intellectual Property is invalid or enforceable without Licensor’s prior written consent, which consent shall
not be unreasonably withheld. If there is a recovery in such action (including a recovery as a result of a settlement), after recovery
of all direct out-of-pocket expenses incurred by the Licensee and Licensor in connection with the action, the Licensee shall pay
to Licensor an cash or cash equivalent received from any alleged infringer equivalent to the royalties which Licensor would have
received if such alleged infringer had been a Sublicensee.

 

 

 

 

    	 	5	 

     

    

 

	 	8.2	Infringement of Third Party Rights. If the Licensee or Licensor receive notice of a claim or action by a third party
alleging infringement of such third party’s rights in connection with the development, manufacture, use, marketing, or sale
of a Licensed Product by the Licensee or their Sublicensee, the Licensee shall have the right to conduct the legal defense, but
shall not enter into any disposition with respect thereto, or enter into any settlement agreement that admits that any Licensed
Product infringes any third party right without Licensor’s prior written consent to such disposition, which consent shall
not be unreasonably withheld. All costs of the Licensee’s defense, and any damages awarded or amounts paid in settlement
in any such claim shall be the sole responsibility of the Licensee. Licensor shall cooperate with the Licensee if requested by
the Licensee in its defense of such infringement claim or action, provided that Licensee shall reimburse Licensor for all out-of-pocket
expenses, including attorneys’ fees, expenses, and expert witness fees incurred by Licensor in providing such cooperation.

 

	 	8.3	Indemnification. Subject to the notification provisions of Section 8.4 below, the Licensee shall defend and hold
harmless Licensor against a third party infringement claim or action which results from the development, manufacture, use, marketing,
or sale of a Licensed Product by the Licensee or their Sublicensee, and indemnify Licensor against the cost of such defense undertaken
by the Licensee, including attorneys’ fees and all other legal expenses, costs, expert witness fees, and damages awarded
or amounts paid in settlement in any such claim or action. Such indemnification shall include attorneys’ fees for independent
counsel retained by Licensor if Licensor deems such separate independent counsel to be necessary as a result of conflicts of interest
with the Licensee, but only in connection with services rendered in connection with matters with respect to which the parties have
adverse interests. The Licensee’s indemnification shall not include indemnification to the extent to which such infringement
is directly caused by Licensor prior to the date of this Agreement.

 

	 	8.4	Notification. In the event that any claim is asserted against Licensor or the Licensee (or any of their respective
officers, directors, trustees, employees, agents, or representatives), or if any such person is made a party defendant in any action
involving a matter which is the subject of Licensor’s indemnification as set forth above, or if either Party becomes aware
of a claim or patent which might provide the basis for a third party’s claim of infringement against Licensee for the development,
manufacture, use, marketing, or sale of a Licensed Product, then such Party shall give written notice to the other within thirty
(30) days of having learned of such, or within ten (10) days of the receipt of a written complaint or formal pleading regarding
the same.

 

 9. TERM AND TERMINATION OF AGREEMENT

 

	 	9.1	Term. The term of the license granted under this Agreement shall continue for the life of the Intellectual Property,
unless terminated sooner under the provisions of this Agreement.

 

	 	9.2	Termination by Licensor. In addition to any other rights of termination set forth in this Agreement, and subject
to any applicable cure periods prescribed herein, Licensor may in his sole discretion terminate this Agreement in the event that:

 

		a)	The Licensee fail to make payments when due of any amounts owed to Licensor under this Agreement
and the Licensee does not correct such failure within thirty (30) business days after receipt of written notice of such failure
is delivered to the Licensee;

		b)	The Licensee or their Sublicensee have not commercialized a Licensed Product after a period of
three (3) years from the Effective Date;

		c)	The Licensee commit a breach of any other obligation of this Agreement or related Party agreement
which is not cured (if capable of being cured) within thirty (30) days after receiving notice of such;

		d)	The Licensee or their Sublicensee intentionally provide any materially false report, in which event
such termination shall be effective thirty (30) days after written notice to Licensee; or,

		e)	The Licensee become insolvent or a petition in bankruptcy is filed against the Licensee and is
consented to, acquiesced, and remains undismissed for ninety (90) days; or Licensee makes a general assignment for the benefit
of creditors, or a receiver is appointed for the Licensee, and the Licensee do not return to solvency before the expiration of
said thirty (30) day period set by the notice, in which event such termination shall be effective thirty (30) days after written
notice to the Licensee.

 

 

 

    	 	6	 

     

    

 

	 	9.3	Conversion to Non-Exclusive License. In addition to the provision set forth in Section 9.2 d) above, Licensor shall
have the option, at its sole discretion, to convert the license set forth in this Agreement to a non-exclusive license if the
Licensee or their Sublicensee have not commercialized a Licensed Product after a period of three (3) years from the Effective
Date.

 

	 	9.4	Termination by Licensee. The Licensee shall have the option to terminate this Agreement upon providing sixty (60)
days’ written notice to Licensor.

 

	 	9.5	Obligations on Termination.

 

		9.5.1.	Rights Termination. Upon termination of this Agreement and except as otherwise expressly
provided herein, all of the rights and licenses granted to Licensee under the terms of this Agreement shall terminate. The Licensee
shall assign any sublicenses granted under this Agreement to Licensor. All rights licensed or transferred by Licensor to the Licensee
hereunder which are subject to termination shall revert to Licensor, and the Licensee agree to execute all instruments reasonably
necessary and desirable to revest said rights in Licensor.

 

		9.5.2.	Regulatory Records. Upon termination, the Licensee shall transfer ownership and possession
of all records and documents of Licensee filed with regulatory authorities relating to the Licensed Products.

 

		9.5.3.	Return of Confidential Material. Upon termination, the Licensee and their Sublicensee shall
return all Confidential Information, including any knowhow relating to the Intellectual Property, transferred to the Licensee by
Licensor. The Licensee and their Sublicensee shall maintain confidentiality and not use any such information for a period of five
(5) years after termination of this Agreement.

 

		9.5.4.	Unsold Inventory. In the event this Agreement is terminated for any reason, the Licensee
and their Sublicensee shall have the right to sell or otherwise dispose of their stock of any Licensed Products, subject to the
obligation of the Licensee to pay Licensor the payments as provided in Section 4 of this Agreement. The Licensee shall immediately
discontinue any additional production of the Licensed Products.

 

		9.5.5.	Sublicensee. In the event that the license granted to the Licensee under this Agreement
is terminated, any sublicenses granted to Sublicensee shall remain in full force and effect, provided that the Sublicensee is not
then in breach of its sublicense agreement, and the Sublicensee agrees to be bound to Licensor as a licensee under the terms and
conditions of the agreement, in which case Licensor and Sublicensee shall enter into appropriate agreements or amendments to the
sublicense agreements to substitute Licensor for the Licensee as the licensor.

 

	 	9.6.	Other Rights. Termination of this Agreement for any reason shall not release any Party hereto from any liability
which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such
termination, nor preclude either party from pursuing any rights and remedies it may have hereunder or at law or in equity which
accrued or are based upon any event occurring prior to such termination, including, without limitation, Licensee’s obligation
to pay all royalties or other payments and/or reimbursements specified in Section 4. The rights provided in. this Section shall
be in addition and without prejudice to any other rights which the parties may have with respect to any breach or violations of
the provisions of this Agreement.

 

	 	9.7	Jointly Owned Improvements and New Inventions.

 

		9.7.1.	After termination of this Agreement, each Party shall have a perpetual right to make, have made,
use, import, offer for sale, and sell all jointly owned Improvements and New Inventions, without the consent of and without accounting
to the other Party.

 

 

 

 

    	 	7	 

     

    

 

		9.7.2.	If after termination of this Agreement, either Party desires to apply for a patent on any jointly
owned Improvement or New Invention, such Party shall advise the other Party in writing of its intent, and the other Party shall
notify the first Party in writing within thirty (30) days of such notice whether it elects to join the first Party in seeking patent
protection. If the other Party elects to not join in seeking patent protection, it shall promptly assign to the first Party its
entire right, title and interest in and to the jointly owned Improvement or New Invention. If the other Party elects to join in
seeking patent protection, the Parties shall jointly select patent counsel to prepare and prosecute the patent application, and
all expenses incurred in connection with such filing and prosecution shall be shared equally by Licensee and Licensor, provided,
the Party providing the original notice of intent to file the application shall have the primary responsibility for directing the
patent prosecution. The Parties shall fully cooperate with one another and keep each other fully informed as to the preparation,
filing and prosecution of all such patent applications. If at any time after the Parties have jointly filed such a patent application,
either Party decides that it has no further interest in the application or any patent granted thereon, it may assign to the other
Party its entire right, title and interest in and to the Improvement or New Invention that is the subject thereof, the application
and any patent granted thereon, and shall thereupon be relieved of any liability for any of the above-mentioned expenses arising
subsequent to its assignment.

 

		9.7.3.	In the event that after termination of this Agreement, either Party desires to bring any legal
action against any third party for infringement of any jointly owned patent, the other Party agrees to cooperate as reasonably
necessary in such action, including executing any papers necessary for pursuit of such legal action and joining as a Party to a
lawsuit if necessary. Any recovery obtained for the patent infringement shall be retained by the Party initiating such action after
pro rata reimbursement of each party's reasonable expenses incurred in bringing, participating in or cooperating in such action.
If the other Party desires to participate in bringing any such action for infringement, the Parties shall agree in advance upon
a reasonable allocation of fees, costs and recoveries.

 

		9.7.4.	In the event that after termination of this Agreement, the validity of any jointly owned patent
is challenged in any forum or proceeding, each Party shall have the option of defending such challenge. If both Parties elect to
defend, they shall share equally in the legal fees, costs and liabilities incurred in such defense. If either Party elects to not
defend such patent, or decides at any time during the defense that it has no further interest in the patent, it may assign to the
other Party its entire right, title and interest in the patent, and shall thereupon be relieved of any liability for any legal
fees and costs incurred subsequent to its assignment.

 

 10. INDEMNIFICATION AND WARRANTIES

 

	 	10.1	Disclaimers. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, LICENSOR DISCLAIMS ALL WARRANTIES WHATSOEVER, WITH
RESPECT TO THE INTELLECTUAL PROPERTY, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES
AS TO THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENT CLAIMS (ISSUED OR PENDING), OR THAT THE MANUFACTURE,
USE OR SALE OF THE LICENSED PRODUCT(S) AND USE OF THE INTELLECTUAL PROPERTY WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK,
OR OTHER RIGHTS. IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL. OR CONSEQUENTIAL LOSSES OR DAMAGES,
EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. LICENSEE TAKES THE INTELLECTUAL
PROPERTY “AS-IS,” “WITH ALL FAULTS,” AND “WITH ALL DEFECTS” AND EXPRESSLY WAIVES ALL
RIGHTS TO MAKE ANY CLAIM WHATSOEVER AGAINST LICENSOR FOR WARRANTY OF ANY KIND RELATING TO THE INTELLECTUAL
PROPERTY SUBJECT TO THE REPRESENTATIONS MADE HEREIN. IN NO CASE SHALL LICENSOR’S LIABILITY FOR DAMAGES OF ANY TYPE
EXCEED THE TOTAL ROYALTIES WHICH HAVE ACTUALLY BEEN PAID TO LICENSOR BY LICENSEE AS OF THE DATE OF FILING OF THE ACTION AGAINST
LICENSOR WHICH RESULTS IN A SETTLEMENT OR AWARD OF DAMAGES.

 

	 	10.2	Indemnity. With the exception of infringement claims or actions covered by Section 8, Licensee shall defend, indemnify,
and hold harmless Licensor from and against any and all liabilities, claims, suits, damages, and expenses of any nature related
to a third party claim in connection with (i) the use by the Licensee or their Sublicensee of the Intellectual Property; (ii) the
development, manufacture, use, marketing, sale, or other disposition of any Licensed Products by the Licensee or their Sublicensee,
or any statement or breach of any representation or warranty made by the Licensee or their Sublicensee with respect thereto; or
(iii) resulting from or arising out of the exercise by Licensee of this license or any sublicense granted by Licensee pursuant
to this Agreement. In the event of such indemnification, Licensor shall reasonably cooperate with the Licensee in defending any
such claims. Licensor shall be entitled to receive information regarding the status of any such matter, and shall be entitled to
retain counsel on its own behalf at Licensee’s expense, in addition to counsel retained by Licensee to defend Licensor, if
Licensor is named a party, and if Licensor deems such separate independent counsel to be necessary as a result of conflicts of
interest with the Licensee, or if Licensor is not satisfied with the defense provided by the Licensee for any reason.

 

 

 

 

    	 	8	 

     

    

 

	 	10.3	Insurance.

 

		10.3.1.	The Licensee, at their sole cost and expense, shall purchase and maintain in effect and shall require
their Sublicensee to purchase and maintain in effect comprehensive or commercial form general liability insurance (contractual
liability and products liability included on a world-wide basis) insuring its and their activities in connection with clinical
trials, marketing approvals, and covering all claims with respect to any Licensed Products manufactured or sold within the term
of any license granted hereunder, and professional liability (errors and omissions), and workers’ compensation as required
by law and automobile liability, which policies shall, if required by the Licensor in writing: (i) be in such form of coverage
and written by such company licensed to conduct business in the State of California as Licensor shall reasonably approve, (ii)
provide that such policy is primary and not excess or contributory with regard to other insurance Licensor may have, (iii) provide
at least thirty (30) days’ notice to Licensor of cancellation, (iv) include Licensor as additional named insureds under Licensee’s
general liability and automobile liability policies, and (v) have the following minimum limits: Comprehensive General Liability
including products and completed operations coverage and contractual liability (minimum $1 million each occurrence, $20 million
annual aggregate). In the event the Licensee cannot obtain such insurance, or cannot obtain such insurance at a reasonable price,
it shall obtain insurance in an amount to reasonable to cover the Licensee in the event of a covered event, based on the then-current
operations of the company. Such insurance shall be written to cover claims incurred, discovered, manifested or made during or after
expiration of this Agreement. The Licensee shall have this insurance in place prior to beginning development on a Licensed Product
and at such time will furnish a certificate of such insurance to Licensor within thirty (30) days thereafter. The Licensee shall
obtain such additional insurance coverage as shall be reasonably requested by Licensor, and reasonably agreed to by the parties,
provided that Licensor shall not request changes in such coverage more frequently than annually.

 

		10.3.2.	The Licensee expressly waive any right of subrogation that it may have against Licensor resulting
from any liabilities, claims, suits, damages, and expenses of any nature for which Licensee has agreed to indemnify Licensor or
hold Licensor harmless under this Section.

 

	 	10.4.	Representations and Warranties of Licensor. Licensor represents, warrants, and covenants to the Licensee as follows:

 

		a)	Licensor warrants that Licensor has the rights, ownership, titles and interests, legal and equitable,
necessary in the Intellectual Property to grant the Licensee the exclusive license and rights described herein.

		b)	The license granted to the Licensee under this Agreement is the only license granted by Licensor
with respect to the Intellectual Property and during the term of this Agreement Licensor shall not grant any third party rights
inconsistent with the rights granted Licensee herein.

		c)	There are no pending, and to the knowledge of Licensor as of the Effective Date, any threatened
actions, claims, or proceedings in any way relating to the Intellectual Property.

 

	 	10.5	Representations and Warranties of the Licensee. The Licensee represent, warrant, and covenant to Licensor as follows:

 

		a)	The License is a corporation (Vivakor) and duly organized, validly existing and in good standing
under the laws of the State of Nevada having full Corporate power to conduct each business as presently conducted, and to enter
into and consummate the transactions contemplated by this Agreement.

		b)	The execution, delivery and performance under this Agreement by the Licensee has been duly authorized
by all required corporate action, do not constitute a breach, default or violation of any of the provisions of Licensee’s
Articles of Incorporation, Bylaws or other charter documents, or any other agreement, law, or regulation to which it may be a party
or by the terms of which it may be bound.

 

 

 

 

    	 	9	 

     

    

 

 11. MISCELLANEOUS

 

	 	11.1	Choice of Law. This Agreement will be governed by the laws of the State of California.

 

	 	11.2	Compliance with Laws and Regulations. The Licensee shall use reasonable efforts to comply with all foreign and United
States federal, state and local laws and regulations applicable to the testing, production, transportation, packaging, labeling,
export, sale and use of the Licensed Products. In particular, Licensee shall be responsible for assuring compliance with all U.S.
export laws and regulations applicable to this license and the Licensee’s activities hereunder. The Licensee shall be responsible
for all taxes, duties, and other governmental charges, however, designated, which are now or hereafter imposed by any such authority
(a) by reason of the performance by the Licensee of their obligations under this Agreement, or the payment of any amounts by the
Licensee to Licensor under this Agreement, (b) based on the Intellectual Property or Licensed Products, or (c) relating to the
import of the Licensed Products into any such territory. Licensor agrees to use reasonable efforts to cooperate with Licensee at
Licensee’s expense, in connection with any filings required by any governmental entity.

 

	 	11.3	Notices. Any notice, report, request or other communication required or permitted to be given under this Agreement
by a Party to the other parties shall be either hand-delivered (including delivery by courier), or mailed by first-class registered
or certified mail (airmail if internationally), with return receipt requested, and addressed as follows:

 

	 	To Licensee:	Vivakor, Inc.
	 	 	2 Park Plaza,
Suite 800
	 	 	Irvine, CA 92614
	 	 	Tel: 949-281-2606
	 	 	Fax:
	 	 	 
	 	With a copy to:	Law Offices of Craig V. Butler
	 	 	300 Spectrum Center Drive, Suite 300
	 	 	Irvine, CA 92618
	 	 	Attn. Craig V. Butler
	 	 	Fax: (949) 209-2545
	 	 	Email: cbutler@craigbutlerlaw.com
	 	 	 
	 	To Licensor:	BGreen, LLC
	 	 	12123 Petersenbluff
Dr
	 	 	Riverton, UT
84065
	 	 	801-502-3373
	 	 	 
	 	With a copy to:	_____________________________
	 	 	_____________________________
	 	 	_____________________________

 

Each Party
may designate in writing a new address to which any notice may thereafter be given. Any notice sent by registered or certified
mail shall be deemed to have been given at the time of the receipt thereof by the other Party or three (3) calendar days after
the time of mailing, whichever is earlier.

 

 

 

 

    	 	10	 

     

    

 

	 	11.4	Entire Agreement. This Agreement contains the entire agreement with respect to the subject matter hereof and supersedes
any and all prior agreements, written or oral with respect thereto.

 

	 	11.5	Waivers and Amendments; Non-Contractual Remedies; Preservation of Remedies. This Agreement shall not be modified
or amended except pursuant to an instrument in writing executed and delivered on behalf of each Party to be bound. No delay on
the part of any Party, in exercising any right hereunder shall operate as a waiver thereof. Neither any waiver on the part of any
Party of any such right, nor any single or partial exercise of any such right shall preclude any further exercise thereof or the
exercise of any other such right unless waived in writing. The rights and remedies hereunder provided are cumulative and except
as otherwise provided herein are not exclusive of any rights or remedies that any party may otherwise have at law or in equity.
The rights and remedies of any party based upon, arising out of or otherwise in respect of any inaccuracy in or breach of any representation,
warranty, covenant or agreement contained in this Agreement shall in no way be limited by the fact that the act, omission, occurrence,
or other state of facts upon which any claim of any such inaccuracy or breach is based may also be the subject matter of any other
representation, warranty, covenant or agreement contained in this Agreement (or in any other agreement between the Parties) as
to which there is no inaccuracy or breach.

 

	 	11.6	Binding Effect; No Assignment. This Agreement shall be binding upon and inure to the benefit of the parties named
herein and their respective successors and permitted assigns. The parties may not assign either this Agreement or any of its rights,
interests, or obligations hereunder without the prior written approval of the other party.

 

	 	11.7	Severability. If any term or provision in this Agreement or the application thereof shall be held invalid, void or
unenforceable, the remainder of such term or provision shall remain in full force and effect, and the invalid, void, or unenforceable
term or provision shall be reformed to the extent possible in order to give its intended effect and/or meaning.

 

	 	11.8	Method of Dispute Resolution. In the event that there arises any disagreement or dispute between the Parties that
cannot be amicably resolved and which relates to the interpretation, enforcement, or violation of the terms of this Agreement,
then all suits and special proceedings hereunder be construed in accordance with and under and pursuant to the laws of the State
of Utah and that in any action, special proceeding or other proceedings that may be brought arising out of, in connection with
or by reason of this Agreement, the law of the State of Utah shall be applicable and shall govern to the exclusion of the law of
any other forum, without regard to the jurisdiction on which any action or special proceeding may be instituted. If any legal action
is filed by either party regarding this Agreement, the exclusive jurisdiction for such action shall be the state or federal courts
sitting in and for the County of Salt Lake City, State of Utah. The Parties hereby consent to such exclusive jurisdiction and venue.

 

	 	11.9.	Headings. The headings in this Agreement are for reference only and shall not affect
the interpretation of this Agreement.

 

	 	11.10	Construction. The parties have participated jointly in the negotiation and drafting of this Agreement. In the event
an ambiguity or question of intent or interpretation arises, the Agreement shall be construed as if drafted jointly by the parties
and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions
of this Agreement.

 

	 	11.11	Confidential Information. Except as expressly provided herein, the Parties agree that, for the term of this Agreement
and for five (5) years thereafter, the Recipient shall keep completely confidential and shall not publish or otherwise disclose
and shall not use for any purpose except for the purposes contemplated by this Agreement any Confidential Information furnished
to it by the Disclosing Party hereto pursuant to this Agreement. Each Party hereto may use or disclose Confidential Information
disclosed to it by the other Party to the extent such use or disclosure is reasonably necessary in filing or prosecuting patent
applications, prosecuting or defending litigation, complying with applicable governmental regulations or otherwise submitting information
to tax or other governmental authorities, conducting clinical trials, or making a permitted sublicense or otherwise exercising
its rights hereunder, provided that if a Party is required to make any such disclosure of another Party’s Confidential Information,
other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the latter Party of such disclosure
and, save to the extent inappropriate in the case of patent applications, will use its best efforts to secure confidential treatment
of such information prior to its disclosure (whether through protective orders or otherwise.) Except as expressly provided herein,
each Party agrees not to disclose any terms of this Agreement to any third party without the consent of the other Party; provided
disclosures may be made as required by securities or other applicable laws, or to actual or prospective investors or corporate
partners, or to a Party’s accountants, attorneys and other professional advisors.

 

 

 

    	 	11	 

     

    

 

	 	11.12	Publicity. Unless required by federal and/or state law or regulation, no Party shall
release any materials containing the name of another Party or any of its employees without the prior approval by an authorized
representative of such Party, which approval shall not be unreasonably withheld. The Parties agree to make a mutually-agreed press
release regarding this Agreement promptly following the Effective Date. Should a Party reject a proposed news release, the Parties
agree to discuss the reasons for such rejection, and every effort shall be made to develop an appropriate informational news release.

 

	 	11.13	Further Assurances. Each Party to this Agreement shall, at the request of the other,
furnish and deliver such documents, or other further assurances as the requesting Party shall reasonably request as necessary
or desirable to effect complete consummation of this Agreement and the transactions contemplated hereby.

 

	 	11.14	Force Majeure. Neither Party shall lose any rights hereunder or be liable to the other
party for damages or losses (except for payment obligations) on account of failure of performance by the defaulting party if the
failure is caused by war, strike, fire, Act of God, earthquake, flood, lockout, embargo, governmental acts or orders or restrictions,
where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct
of the non-performing party and the non-performing party has exerted all reasonable efforts to avoid or remedy such force majeure;
provided, however, that in no event shall any party be required to settle any labor dispute or disturbance.

 

	 	11.15	Survival. The following obligations shall survive the termination of this Agreement:
(a) the Licensee’s obligation to supply reports covering the time periods up to the date of termination; (b) Licensor’s
right to receive payments and fees, accrued or accruable, from payments at the time of any termination; (c) The Licensee’s
obligation to maintain records, and Licensor’s right to have those records inspected; (d) any cause of action or claim of
either party, accrued or to accrue because of any action or omission by the other; (e) The Licensee’s obligations stated
in Sections 5, 8, 9.5, 9.6, 10.1,10.2, 11.1, 11.3, 11.11, 11.12, 11.13, 11.14 of this Agreement; and (f) Licensee’s obligations
to return all materials given to it by Licensor.

 

 

 

 

 

[signature page follows]

 

 

 

 

 

 

 

 

    	 	12	 

     

    

 

IN WITNESS WHEREOF,
the Parties have executed this Agreement as of the date set forth below:

 

 

 

	Licensor:	BGreen, LLC
	 	a Utah limited liability
company
	 	 
	 	/s/ Brenner Adams
	 	By: Brenner Adams
	 	Its: Manager
	 	 
	 	 
	Licensee:	Vivakor, Inc.
	 	a Nevada corporation
	 	 
	 	/s/ Matt Nicosia
	 	By: Matt Nicosia
	 	Its: CEO

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	13	 

     

    

 

Exhibit A

 

Description of the Cavitation Technology

 

 

A system of motors, pumps, spinning plates
or plate-like devices and blenders that are used to break down the long chain hydrocarbon of mostly oil based fluids to improve
their American Petroleum Institute (“API”) rating with a target of 3 to 30 degrees of gravity. 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]